|
Court Orders FDA to Approve Watson’s Actos ANDA, Award Exclusivity
A district court has ordered the FDA to immediately approve Watson’s ANDA for a generic of Takeda’s billion-dollar diabetes treatment Actos.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAsTwo Ex-FDA Commissioners Say Generic Makers Don’t Get Free Pass on State Suits FDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone GenericsCephalon’s Fentora Patents Upheld But Court OKs Watson’s Generic
|
Subscribe
Archives